Skip to main content
OpenTrials
Completed

NCT Number: NCT02939209

Pre-emptive Opioid Treatment to Prevent Rebound Pain After Arthroscopic Rotator Cuff Repair and/or Acromioplasty Under General Anesthesia and Interscalene Block

Arthroscopic shoulder rotator cuff repair and acromioplasty are associated with severe postoperative pain. The interscalene block (ISB) is commonly used for this type of surgery, providing analgesia by anesthetizing the nerves that supply the shoulder. Although the nerve block provides extremely effective analgesia for the first 6-8 hours, patients experience severe pain once its effect has regressed. This study will assess whether a single dose of oral hydromorphone controlled release, given to overlap the waning of the ISB, will improve postoperative pain control and reduce the incidence of rebound pain.

Seventy patients undergoing rotator cuff repair will receive standardized ISB and general anesthesia for the surgery. Six hours (+/- 1 hour) after ISB, the patients will randomly receive either a single oral dose of 2 mg Hydromorphone (immediate release formulation) or placebo. The patient will be then discharged home with a prescription for multimodal analgesia, which is the standard of care. Patients will be given a diary to record their pain scores and track use of analgesic medications for 24 hours. Twenty-four hours after the ISB, the patients will receive a phone call from a nurse as per the standard of care. During this phone call, questions will be asked about their pain control.

If a single dose of pre-emptive hydromorphone is demonstrated to be safe and effective, it will lead to change in practice of how we manage pain after rotator cuff repair. Furthermore, the finding of this study may apply to similar surgical procedures (such as elbow, knee and ankle repairs) that are associated with rebound pain when the nerve block wears off.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Nova Scotia Health Authority Queen Elizabeth II Hospital Halifax Infirmary site, Halifax, Nova Scotia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-65
  • scheduled to receive ISB and general anesthesia as a day surgery patient for rotator cuff repair and acromioplasty, as a part of planned routine care

Exclusion criteria

  • Allergy, sensitivity, or absolute contraindications to any of the medications involved in the study
  • preexisting CNS depression, or taking regularly medication that cause CNS depression
  • preexisting cognitive deficits, dementia, or delirium
  • severe respiratory comorbidities (e.g. chronic obstructive pulmonary disease, pneumonia, respiratory failure)
  • sleep disordered breathing (diagnosed OSA, obesity hypoventilation syndrome)
  • pregnancy and breast feeding
  • history of chronic pain or regular (at least once daily) opioid use preoperatively
  • renal impairment - CrCl ≤60 mL/minute
  • not fluent in English to be able to participate in the study process, including consent and phone interview
  • Body Mass Index >35
  • inability to take oral medication.

Treatment and study plan

Hydromorphone Hcl 2Mg Tab

Drug

Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.

Placebo

Drug

Patients may be randomized to placebo.

Primary outcomes

  1. Worst pain score

    Time frame: 24 hours post interscalene block

    We will investigate whether a single dose of hydromorphone 2 mg, given at six hours after single-shot ISB for rotator cuff repair, reduces worst pain score (NRS) in first 24 hours by two points or more as measured on 11 point (0-10) NRS scale when compared to placebo, with perioperative multimodal analgesia used in both groups.

Secondary outcomes

  1. Time to first rescue opioid use, within 24 hours after ISB insertion

    Time frame: 24 hours post interscalene block

  2. Total rescue hydromorphone consumption, within 24 hours after ISB insertion

    Time frame: 24 hours post interscalene block

  3. Two hourly pain score (burden of pain) while the patient is awake

    Time frame: 24 hours post interscalene block

  4. Incidence of clinically significant nausea and vomiting after the dose of study drug

    Time frame: 24 hours post interscalene block

  5. Number of patients failing discharge from hospital due to pain, nausea, vomiting or sedation

    Time frame: 24 hours post interscalene block

  6. Number of patients needing emergency room visit due to pain within 24 hours of surgery

    Time frame: 24 hours post interscalene block

  7. Number of patients needing hospital readmission due to pain within 24 hours of surgery

    Time frame: 24 hours post interscalene block

Sponsors and collaborators

Lead sponsor

Vishal Uppal

Other

Registry information

Official study title

Preventing Rebound Pain After Arthroscopic Rotator Cuff Repair and/or Acromioplasty Under General Anesthesia and Interscalene Block: A Randomized Controlled Trial of Pre-emptive Opioid Treatment Compared to Placebo

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Oct 19, 2016
Registry last updated
Nov 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.